Seelos Therapeutics Company Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders.
The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease.
Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
| Country | United States |
| Founded | 2016 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 16 |
| CEO | Raj Mehra |
Contact Details
Address: 300 Park Avenue New York, Nevada 10022 United States | |
| Phone | 646 293 2100 |
| Website | seelostherapeutics.com |
Stock Details
| Ticker Symbol | SEELQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Raj Mehra | Chief Executive Officer |
| Michael Golembiewski | Chief Financial Officer |